Quick Answer
Viridian Therapeutics, Inc.DE reported Total Revenue of $4.00 million for fiscal year 2017.
Viridian Therapeutics, Inc.DE — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | — | — | — | — | — | — |
| Net Income | -$342.60M -26.9% |
-$269.95M -13.6% |
-$237.73M -83.0% |
-$129.87M -63.5% |
-$79.41M +28.3% |
-$110.72M -164.4% |
| Diluted EPS | — | — | -$5.31 -31.1% |
-$4.05 +39.2% |
-$6.66 +78.6% |
-$31.13 |
| Total Assets | $899.42M +21.1% |
$742.40M +51.4% |
$490.42M +12.7% |
$435.09M +113.6% |
$203.71M +55.2% |
$131.25M +333.7% |
| Cash and Equivalents | — | — | — | — | — | — |
| Long-Term Debt | — | $20.58M +1.9% |
$20.20M +335.0% |
$4.64M | $0.00 | — |
| Stockholders Equity | $722.17M +7.5% |
$671.64M +51.9% |
$442.02M +11.9% |
$395.06M +110.5% |
$187.72M +56.4% |
$120.04M +661.9% |
| R&D Expense | — | — | — | — | — | — |
| Operating Income | -$363.39M -21.5% |
-$299.04M -17.5% |
-$254.45M -89.5% |
-$134.30M -68.5% |
-$79.73M +27.8% |
-$110.38M -162.9% |
| Shares Outstanding | 101.83M +25.7% |
80.99M +50.0% |
53.99M +30.7% |
41.31M +72.7% |
23.92M +465.4% |
4.23M +82.1% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | March 31, 2018 | $4.78M | +935.5% | +193.3% |
| Net Income | September 30, 2025 | -$34.60M | +54.9% | +65.7% |
| Diluted EPS | September 30, 2024 | -$1.15 | -5.5% | -12.7% |
| Total Assets | September 30, 2025 | $577.14M | -25.2% | -0.9% |
| Cash and Equivalents | September 30, 2019 | $24.86M | -21.6% | +3.5% |
| Long-Term Debt | September 30, 2025 | $20.89M | +1.8% | +69.1% |
| Stockholders Equity | September 30, 2025 | $502.97M | -28.9% | -2.4% |
| R&D Expense | September 30, 2020 | $3.11M | -65.5% | -18.9% |
| Operating Income | September 30, 2025 | -$40.01M | +52.1% | +62.5% |
| Shares Outstanding | September 30, 2025 | 82.23M | +3.8% | +0.7% |
- Viridian Therapeutics, Inc.DE reported Total Revenue of $4.00 million for fiscal year 2017.
- Viridian Therapeutics, Inc.DE showed an increase of +15.1% in Total Revenue compared to the prior fiscal year.
- Viridian Therapeutics, Inc.DE reported Net Income of -$342.60 million for fiscal year 2025.
- Viridian Therapeutics, Inc.DE showed a decrease of -26.9% in Net Income compared to the prior fiscal year.
- Viridian Therapeutics, Inc.DE reported Diluted EPS of $5.31 per share (loss) for fiscal year 2023.
- Viridian Therapeutics, Inc.DE showed a decrease of -31.1% in Diluted EPS compared to the prior fiscal year.
- Viridian Therapeutics, Inc.DE reported Total Assets of $899.42 million for fiscal year 2025.
- Viridian Therapeutics, Inc.DE showed an increase of +21.1% in Total Assets compared to the prior fiscal year.
- Viridian Therapeutics, Inc.DE reported Cash and Equivalents of $32.61 million for fiscal year 2018.
- Viridian Therapeutics, Inc.DE showed a decrease of -31.3% in Cash and Equivalents compared to the prior fiscal year.
- Viridian Therapeutics, Inc.DE reported Long-Term Debt of $20.58 million for fiscal year 2024.
- Viridian Therapeutics, Inc.DE showed an increase of +1.9% in Long-Term Debt compared to the prior fiscal year.
- Viridian Therapeutics, Inc.DE reported Stockholders Equity of $722.17 million for fiscal year 2025.
- Viridian Therapeutics, Inc.DE showed an increase of +7.5% in Stockholders Equity compared to the prior fiscal year.
- Viridian Therapeutics, Inc.DE reported R&D Expense of $34.79 million for fiscal year 2019.
- Viridian Therapeutics, Inc.DE showed an increase of +14.4% in R&D Expense compared to the prior fiscal year.
- Viridian Therapeutics, Inc.DE reported Operating Income of -$363.39 million for fiscal year 2025.
- Viridian Therapeutics, Inc.DE showed a decrease of -21.5% in Operating Income compared to the prior fiscal year.
- Viridian Therapeutics, Inc.DE reported Shares Outstanding of 101.83 million shares for fiscal year 2025.
- Viridian Therapeutics, Inc.DE showed an increase of +25.7% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: